The phylogenetic map from the human kinome demonstrating growth and US FDA acceptance of small molecule kinase inhibitors to tyrosine kinases and serine/threonine kinases for a number of reliable and hematologic malignancies. Opzelura was the 1st topical JAK inhibitor accredited to be used in The